Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.40 |
| ▸ | MTOR | P42345 | 6/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663634 | 0.84 | TUBB4A (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3700292 | 0.84 | TUBB4A (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30851652 | 0.83 | PIK3CA (0.37) | PIK3CAMTORCLK1DYRK1ADYRK1B | |
| SCHEMBL26179779 | 0.83 | TUBB4A (0.42) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18529451 | 0.78 | XPO1 (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL510468 | 0.77 | ABL1 (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31139883 | 0.74 | GABRP (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL20657822 | 0.74 | GABRP (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL26632215 | 0.74 | KMT2A (0.42) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5618068 | 0.73 | ABL1 (0.61) | PKMRAB9AABL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220169648-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-06-02 | — | — | US | disclosed |
| US-11254670-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200231589-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-23 | — | — | US | disclosed |
| WO-2020150676-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-3654982-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | Nuvation Bio Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| CN-111093666-A | 1, 8-naphthyridinone compounds and uses thereof | 诺维逊生物股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| WO-2019018583-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | GiraFpharma LLC (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1771420-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | BARTKOVITZ DAVID J | 2006-01-19 | — | — | US | disclosed |
| WO-2006005548-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254670-B2 | 1,8-naphthyridinone compounds and uses thereof | NME1, ADORA2A, GPR68 | TUBB4A 3815/4885TUBB 3799/4885TUBA3C 4569/4885 |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | TUBB4A 3815/4885TUBB 3799/4885TUBA3C 4569/4885 |
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | CDK2, CCNA2, CDK6 | TUBB4A 1135/4885TUBB 1347/4885TUBA3C 1484/4885 |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NME1, ADORA2A, GPR68 | TUBB4A 3815/4885TUBB 3799/4885TUBA3C 4569/4885 |
| US-20200231589-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | TUBB4A 3815/4885TUBB 3799/4885TUBA3C 4569/4885 |
| US-20220169648-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | TUBB4A 3815/4885TUBB 3799/4885TUBA3C 4569/4885 |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | TUBB4A 3815/4885TUBB 3799/4885TUBA3C 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.